<DOC>
	<DOCNO>NCT01271387</DOCNO>
	<brief_summary>The purpose research study understand whether difference amount tasimelteon ( include breakdown product ) blood individual mild moderate liver disease compare individual normal liver function .</brief_summary>
	<brief_title>Pharmacokinetics Tasimelteon Subjects With Mild Moderate Hepatic Impairment</brief_title>
	<detailed_description>The study employ open-label , parallel-group design . Up 32 subject enrol 3 group : Group 1 consist 8 subject mild hepatic impairment ; Group 2 consist 8 subject moderate hepatic impairment ; Group 3 consist 16 healthy subject match gender , age , smoke status , body mass index , Groups 1 and/or 2 . For group , 21-day screening period , baseline period , single-dose treatment period on-site observation period 36 hour , study completion evaluation conduct last PK blood sample drawn . Each subject receive single 20-mg dose tasimelteon , safety assessment perform .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All Subjects : Ability acceptance provide write informed consent ; Men woman 18 75 year , inclusive ; Subjects Body Mass Index ( BMI ) &gt; 18 &lt; 35 kg/m2 ; Women childbearing potential must use acceptable method birth control ; Willing able comply study requirement restriction ; Subjects mild moderate hepatic impairment : Stable hepatic impairment satisfy criterion Class A B modify ChildPugh classification document medical history ; Subjects Moderate hepatic impairment must also either liver cirrhosis physical sign consistent clinical diagnosis liver cirrhosis Creatinine clearance great 50 mL/min Healthy match control : Matched subject hepatic impairment gender , age , BMI , smoke status Good health determine past medical history , physical examination , electrocardiogram , laboratory test , vital sign urinalysis ; Smokers unable unwilling limit consumption ; Exposure investigational drug , include placebo , within 30 day dose ; Blood Donation loss 400 mL within two month prior dose ; Significant illness within two week prior dose ; History autonomic dysfunction ; History acute chronic bronchospastic disease , include asthma chronic obstructive pulmonary disease , treat treat ; A know hypersensitivity tasimelteon drug similar tasimelteon include melatonin ; Pregnant lactating female ; History drug alcohol abuse within 12 month prior screen History immunocompromise , include positive HIV ( ELISA Western blot ) test result ; Any surgical medical condition might significantly alter absorption , distribution excretion drug ; Clinically significant ECG abnormality vital sign abnormality screen history unstable , severe , clinically significant cardiovascular disease ; Subjects mild moderate hepatic impairment : Clinically significant abnormal finding , consistent clinical disease , upon physical examination , ECG , laboratory evaluation ; Current symptom past history ( within last 6 month ) encephalopathy ; Severe ascites ; Previous surgical portosystemic shunt include transjugular intrahepatic portosystemic shunt ( TIPS ) ; Progressive liver disease within 4 week prior screen . Healthy match control : Use prescription medication within 1 month dosing , OTC medication within 14 day prior dose ; History presence liver disease liver injury ; A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Liver disease</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>